Lisinopril reverses left ventricular hypertrophy through improved aortic compliance

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Research

Background:

• Left ventricular hypertrophy (LVH) is a common complication of essential hypertension.
• Effective antihypertensive treatment is crucial for reversing LVH and improving cardiovascular outcomes.
• Understanding the differential effects of various antihypertensive agents on hemodynamic factors is important.

Purpose of the Study:

• To compare the efficacy of nifedipine and lisinopril in reversing left ventricular hypertrophy in patients with essential hypertension.
• To investigate the distinct hemodynamic mechanisms through which nifedipine and lisinopril exert their effects on LVH.

Main Methods:

• A single-blind crossover study involving 38 essential hypertensive patients with LVH.
• Patients received either nifedipine or lisinopril for 24 weeks, followed by a crossover to the alternative agent for another 24 weeks.
• Measurements included mean arterial pressure, left ventricular mass index, and aortic compliance.

Main Results:

• Both nifedipine and lisinopril significantly reduced mean arterial pressure to a similar extent.
• Lisinopril demonstrated a more rapid decrease in left ventricular mass index compared to nifedipine.
• After 48 weeks, both agents effectively reduced the extent of left ventricular hypertrophy to comparable levels.
• Regression analysis suggested that reduced mean arterial pressure was key for nifedipine's effect, while improved aortic compliance was key for lisinopril's effect.

Conclusions:

• Nifedipine and lisinopril are both effective in reversing hypertensive left ventricular hypertrophy.
• The agents exhibit different impacts on hemodynamic parameters, with nifedipine primarily acting via blood pressure reduction and lisinopril via improved aortic compliance.
• These findings highlight the importance of considering distinct hemodynamic profiles when selecting antihypertensive therapy for LVH.